A new securities class action, filed Wednesday in Manhattan federal court, accused New York City-based health care logistics firm SCWorx Corp. of misleading investors about a supposed deal to buy and resell millions of COVID-19 rapid testing kits.

The lawsuit targeted SCWorx and its CEO Marc Schessel over an April 13 announcement that the company had secured a committed purchase order of two million test kits per week. The deal, SCWorx said at the time, included a provision for additional weekly orders of 2 million units over 23 weeks, valued at $35M per week.